Lifelight

The core of Lifelight's product is remote photoplethysmography (rPPG) technology, which detects subtle, imperceptible changes in facial skin color ("micro blushes") caused by blood flow. This data is then processed in the cloud by proprietary AI algorithms, trained on a large clinical dataset, to calculate vital signs. The technology has been developed over seven years and is protected by multiple patents. Lifelight’s software is available as a Software Development Kit (SDK) that can be integrated into third-party applications, serving clients in remote patient monitoring, telehealth, insurance, and pharmaceuticals. The company's business model is centered on providing this embeddable technology to partners, including the UK's National Health Service (NHS), where it is used for community health screening and in virtual wards.

Lifelight has received significant backing through grants and equity funding, including from Innovate UK and SBRI Healthcare. The technology holds CE Class IIa medical device certification in Europe for blood pressure and pulse measurement and is pursuing FDA clearance in the United States. Lifelight's stated mission is to make healthcare monitoring more accessible and scalable, aiming to address major health issues like undiagnosed hypertension by enabling mass screening at a low cost.